. Author manuscript; available in PMC: 2014 Sep 19.

Published in final edited form as: Hematol Oncol Clin North Am. 2011 Aug;25(4):853–869. doi: 10.1016/j.hoc.2011.05.003

Table 2.

Targeted agents currently under evaluation in selected clinical trials

Agent	Subtype	Trial number
Sunitinib	Metastatic NCCRCC (all types)	NCT 00465179
	Metastatic NCCRCC (all types)	NCT 01034878
	Metastatic PRCC, ChRCC, MRCC	NCT 01219751
Temsirolimus versus sunitinib	Locally advanced and metastatic NCCRCC (all types)	NCT 00979966
Everolimus	Metastatic PRCC	NCT 00688753
	Metastatic NCCRCC (all types)	NCT 00830895
Everolimus versus sunitinib	Metastatic PRCC, ChRCC, CDRCC	NCT 01185366
	Metastatic PRCC, ChRCC	NCT 01108445
Erlotinib	Local and metastatic PRCC	NCT 00060307
Erlotinib and bevacizumab	Hereditary and sporadic metastatic PRCC	NCT 01130519